Caricamento...
Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group
It is expected that the coronavirus disease 2019 (COVID-19) pandemic will leave large deficits in the budgets of many jurisdictions. Funding for other treatments, in particular new treatments, may become more constrained than previously expected. Therefore, a robust health technology assessment (HTA...
Salvato in:
| Pubblicato in: | Value Health |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7534734/ https://ncbi.nlm.nih.gov/pubmed/33127011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jval.2020.09.003 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|